[Federal Register Volume 61, Number 29 (Monday, February 12, 1996)] [Notices] [Pages 5404-5405] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 96-3073] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. ----------------------------------------------------------------------- The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Robert Benson, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7056 ext. 267; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Attenuated Human Rotavirus Vaccine Hoshino, Y., Kapikian, A.Z., and Chanock, R.M. (NIAID) Filed 11 July 95 (priority to 11 Jul 94) Serial No. 08/500,564 (CIP of 08/481,644) Rotaviruses are recognized as the single most important etiologic agent of severe diarrhea in both developed and nondeveloped countries. This invention embodies an attenuated rotavirus as a vaccine. The claims of the invention relate to the generation of a cold-adapted virus that is not efficient in replication at normal human body temperatures and therefore may be capable of stimulating an immune response without causing illness. In a limited clinical trial, administration of a cold-adapted rotavirus vaccine to 26 adults demonstrated that the vaccine was safe, attenuated, and was capable of inducing a virus-specific serologic response. This invention has been PCT filed on July 11, 1995. (portfolio: Infectious Diseases--Vaccines, viral, non-AIDS) Method for Generating Influenza A Viruses Bearing Attenuating Mutations in Internal Protein Genes Murphy, B., Subbarao, K.E., Kawaoka, Y. (NIAID) Filed 7 Jun 95 Serial No. 08/481,631 (CIP of 08/309,521, CIP of 08/123,933) This invention describes a method of producing attenuated Influenza A strains for use as live Influenza A virus vaccine candidates. This method involves the introduction of three temperature-sensitive attenuating mutations into the polymerase basic protein 2 (PB2) gene of Influenza A virus. These mutations are introduced by site-directed mutagenesis at specific sites into a cDNA copy of the PB2 gene. An RNA transcript of this nutant PB2 gene is recovered into an infectious Influenza A virus using a host range restricted helper virus. This attending mutant PB2 gene can be transferred to each new variant of Influenza A virus as it appears in nature. The patent application covering this invention is available for licensing and contains claims to: The methods of producing the attenuated strains; the attenuated strains produced by the methods; and methods of vaccination using the attenuated strains. Viruses containing mutant PB2 genes are also available for licensing. (portfolio: Infectious Diseases--Vaccines, viral, non-AIDS) Attenuated Influenza A Virus Palese, P., Muster, T., Murphy, B.R., Enami, M., Bergmann, M., Subbaro, E.K., Chanock, R.M. (NIAID) Filed 7 Jun 95 (priority to 3 Feb 92) Serial No. 08/480,939 (FWC of 07/939,716) This invention describes the development of a novel live attenuated influenza A virus for use in intranasal vaccines. This virus is unique in that it is a chimera of two influenza strains. This results in an attenuated virus capable of invoking an immune response and therefore protection against influenza. The claims of this invention cover a method for generating the attenuated influenza virus, introducing the viral construct into cell lines, and vaccinating a vertebrate with the attenated virus. Animal studies have demonstrated that infection with the chimeric virus leads to resistance to a challenge with wild-type virus. (portfolio: Infectious Diseases--Vaccines, viral, non-AIDS) Pteridine Nucleotide Analogs as Fluorescent DNA Probes Hawkins, M.E., Pfleiderer, W., Davis, M.D., Balis, F.M. (NCI) [[Page 5405]] Filed 26 May 95 Serial No. 08/451,641 (DIV of 08/245,923) The invention concerns a series of pteridine deoxyribonucleotide analogs which are highly fluorescent and resemble purine nucleotides in chemical structure and properties. The phosphoramidite form of these fluorophores can be site-specifically incorporated into oligonucleotides using conventional DNA synthesis techniques. The fluorescence intensity of the pteridine nucleotide analogs is highly dependent on their physicochemical environment, thus making them ideal for the study of DNA-protein interactions. A real-time assay for HIV integrase has been developed using one of the pteridine nucleotide analogs that resembles guanosine. Other uses foreseen are as fluorescent labels for DNA probes and PCR primers and for investigating protein-DNA interactions. The claims include the phosphoramidite derivatives of the pteridine nucleotide analogs useful as starting materials for oligonucleotide synthesis and oligonucleotides incorporating the pteridine nucleotide analogs. (portfolio: Gene-Based Therapies--Research Tools and Reagents; Gene-Based Therapies-- Diagnostics) Dated: February 1, 1996. Barbara M. McGarey, Deputy Director, Office of Technology Transfer. [FR Doc. 96-3073 Filed 2-9-96; 8:45 am] BILLING CODE 4140-01-M